EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Storm Therapeutics raised £14 million ($18 million), bringing its total series A haul up to £30 million. The money will support preclinical work on modulators of RNA modifying enzymes. Release 

> Scancell revealed Cancer Research UK is planning to run a phase 1/2 trial of its SCIB2-nanoparticle complex in patients with solid tumors. Statement 

> Boehringer Ingelheim Venture Fund and UCB Ventures co-led a seed investment in hearing loss cell therapy startup Rinri Therapeutics. The British biotech will use the money to fund early-stage work on a program intended to reverse neuropathic sensorineural hearing loss. Release  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Slow enrollment in a pediatric trial forced Zealand Pharma to push back a planned filing for FDA approval of its dasiglucagon HypoPal rescue pen. Zealand now expects to submit a NDA early next year. Statement 

> The UKI2S Innovate Accelerator launched with £10 million to support startups in healthcare and other fields. Innovate UK and the UK Innovation & Science Seed Fund joined forces to set up the accelerator. Release 

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.